Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0218 • ACR Convergence 2020
Clinical Outcomes of Earlier versus Delayed Treatment of Iraqi Patients with Rheumatoid Arthritis with Etanercept
Nizar Abdulateef¹, Faiq Gorial¹, Yasameen Humadi², Dina Yasiry³, Fadya Al Derwibee³, Nancy Sunna⁴ and Ali AlJabban⁵, ¹Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ²Baghdad Teaching Hospital, Rheumatology Department, Baghdad, Iraq, Baghdad, Iraq, ³Baghdad Teaching Hospital, Rheumatology Department, Baghdad, Iraq, Baghdad, Iraq, ⁴Pfizer Inc., Amman, Jordan, ⁵Pfizer Inc., Baghdad, Iraq
Background/Purpose: The management of patients with early rheumatoid arthritis (RA), defined by the American College of Rheumatology (ACR) guidelines as patients who have had RA…
Abstract Number: 0235 • ACR Convergence 2020
Safety and Biological Activity of Rozibafusp Alfa in Subjects with Rheumatoid Arthritis: Final Results of a Phase 1b Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study
Lubna Abuqayyas¹, Laurence Cheng¹, Kyong Park¹, Marcia Teixeira dos Santos¹, Barbara Sullivan¹, Hui Wang¹, Yanchen Zhou¹, Vishala Chindalore², Stanley Cohen³, Alan Kivitz⁴, Maximilian Posch⁵ and Jane Parnes¹, ¹Amgen Inc., Thousand Oaks, CA, ²Pinnacle Research Group, Anniston, AL, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁵Charité Research Organisation, Berlin, Germany
Background/Purpose: B-cell activating factor (BAFF) and inducible costimulator ligand (ICOSL) are implicated in autoimmune disease pathogenesis, and clinical findings support their utility as drug targets…
Abstract Number: 0479 • ACR Convergence 2020
Early DAS Response After DMARD-start Increases Probability of Achieving Sustained DMARD-free Remission in Rheumatoid Arthritis
Marloes Verstappen¹, Ellis Niemantsverdriet², Xanthe Matthijssen², Saskia le Cessie² and Annette van der Helm - van Mil³, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Sustained DMARD-free remission (SDFR) is increasingly achievable. The pathogenesis underlying SDFR-development is unknown and patient-characteristics at diagnosis poorly explain whether SDFR will be achieved.…
Abstract Number: 0548 • ACR Convergence 2020
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up
Maria Auxiliadora Martin-Martinez¹, Santos Castañeda², Fernando Sanchez-Alonso³, Carmen García-Gómez⁴, Carlos González_Juanatey⁵, M. Ángeles Belmonte-López⁶, Jesus Tornero-Molina⁷, José Santos-Rey⁸, Carmen Olga Sánchez-González⁹, Estefania Moreno¹⁰, Maria del puerto Moreno-Gil¹¹, Tatiana Cobo-Ibañez¹², Jose Antonio Pinto-Tasende¹³, Jesús Babío-Herráez¹⁴, Gema Bonilla¹⁵, Antonio Juan-Mas¹⁶, Francisco Manero-Ruiz¹⁷, Montserrat Romera-Baurés¹⁸, Javier Bachiller-Corral¹⁹, Eugenio Chamizo-Carmona²⁰, Javier Calvo-Catalán²¹, Raimon Sanmartí²², Celia Erausquin-Arruabarrena²³, Rosario Garcia-Vicuña²⁴, Carmen Barbadillo²⁵, Sergio Ros-Expósito²⁶, Ana Isabel Turrión²⁷, M José González-Fernández²⁸, Jose Miguel Senabre²⁹, Silvia Martínez-Pardo³⁰, Ana Ruibal-Escribano³¹, Emilio Giner-Serret³², Elisabet Berzosa-Sola³³, Julia Martínez-Barrio³⁴, Encarnación Pagán³⁵, M Enriqueta- Peiró³⁶, Sagrario Bustabad-Reyes³⁷, Alba Erra-Durán³⁸, Beatriz González Álvarez³⁹, Ana Cruz Valenciano⁴⁰, Javier Rivera-Redondo⁴¹, Manuel Moreno Ramos⁴², Sergio Rodriguez Montero⁴³, Mercedes Morcillo-Valle⁴⁴, Maria Teresa Navío⁴⁵, Maria Galindo-Izquierdo⁴⁶, Manuel Riera-Soler⁴⁷, Jordi Fiter⁴⁸, Javier Llorca⁴⁹ and Miguel Ángel González-Gay⁵⁰, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ⁴Consorci Sanitari de Terrassa, Barcelona, Spain, ⁵Hospital Lucus Augusti, Lugo, Spain, ⁶Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷University Hospital of Guadalajara. Spain, Madrid, Madrid, Spain, ⁸Hospital Virgen de la Salud, Toledo, Spain, ⁹Hospital Sureste, Madrid, Spain, ¹⁰Universitario Vall D'hebron, Barcelona, Spain, ¹¹Complejo Hospitalario de Cáceres, Caceres, Spain, ¹²Hospital Infanta Sofia, Madrid, Spain, ¹³CHUAC, A Coruña, Spain, ¹⁴Hospital de Cabueñes, Gijón, Spain, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶Hospital Sont Llatzer, Palma de Mallorca, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁰Hospital de Merida, Badajoz, Spain, ²¹Hospital General Universitario Valencia, Valencia, Spain, ²²Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ²³Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁴Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Viladecans, Barcelona, Spain, ²⁷Hospital Universitario de Salamanca, Salamanca, Spain, ²⁸Hospital Dexeus, Barcelona, Spain, ²⁹Hospital de Marina Baixa, Alicante, Spain, ³⁰H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ³¹Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ³²Hospital Obispo Polanco, Teruel, Spain, ³³Hospital del Elda, Alicante, Spain, ³⁴Hospital General Universitario Gregorio Marañón, Madrid, ³⁵Hospital Los Arcos, Murcia, Spain, ³⁶Hospital Marques de Valdecilla, Santander, Spain, ³⁷Hospital Universitario Canarias, Tenerife, Spain, ³⁸Hospital San Rafael, Barcelona, Spain, ³⁹Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴⁰Hospital Severo Ochoa, Madrid, Spain, ⁴¹Instituto Provincial de Rehabilitación, Madrid, Spain, ⁴²Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴³H. Virgen de Valme, Sevilla, Spain, ⁴⁴Hospital El Escorial, Madrid, Spain, ⁴⁵Hospital Infanta Leonor, Madrid, Spain, ⁴⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁷Hospital dos de Maig, Barcelona, Spain, ⁴⁸Hospital Universitario Son Dureta, Palma de Mallorca, Spain, ⁴⁹School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular (CV) event (CVE) in patients with chronic inflammatory rheumatic diseases…
Abstract Number: 0744 • ACR Convergence 2020
Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations with Disease Characteristics, Body Composition, and Physical Functioning
Patrick Gould¹, Babette Zemel², Elena Taratuta³ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³University of Pennsylvania, Philadelphia
Background/Purpose: Rheumatoid arthritis (RA) can lead to changes in body composition, including muscle loss and excess adiposity, which are in turn associated with physical disability.…
Abstract Number: 0761 • ACR Convergence 2020
Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis
Nora Petrovská¹, Klára Prajzlerová¹, Ivana Půtová², Monika Gregová¹, Petra Hánová², Heřman Mann³, Karel Pavelka¹, Jiří Vencovský¹, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: In order to identify the individuals at risk of imminent progression to rheumatoid arthritis (RA), EULAR has established a definition of clinically suspect arthralgia…
Abstract Number: 0778 • ACR Convergence 2020
Bacterial Families Lachnospiraceae/Ruminococcaceae Are Immunologically Targeted in Individuals At-risk for RA and a Specific Strain Is Arthritogenic in Monocultured Gnotobiotic Mice
Meagan Chriswell¹, Jennifer Seifert², Lisa Blum³, Michelle Bloom³, Marie Feser⁴, M Kristen Demoruelle⁵, Jill Norris⁶, Kevin D. Deane⁷, Eddie James⁸, Jane Buckner⁸, William Robinson³, V. Michael Holers⁵ and Kristine Kuhn⁹, ¹UC Denver SOM, Denver, CO, ²UC Denver, Littleton, CO, ³Stanford University, Palo Alto, CA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵University of Colorado, Denver, CO, ⁶Colorado School of Public Health, Aurora, CO, ⁷2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁸Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁹University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating autoantibodies, including anti-CCP and RF, develop years before physical manifestations of rheumatoid arthritis (RA), with several lines of evidence suggesting that these autoantibodies…
Abstract Number: 0795 • ACR Convergence 2020
Minimum Clinically Important Improvement in Patients with Rheumatoid Arthritis Associates with Gut Microbiome
Vinod Gupta¹, Kevin Cunningham², Benjamin Hur¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Within the past decade, there have been several major discoveries in cross-sectional gut microbiome studies suggesting that dysbiosis of the gut microbiota is a…
Abstract Number: 0811 • ACR Convergence 2020
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Janet Pope¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Serge Perrot⁴, Yvonne Lee⁵, Anthony Sebba⁶ and Ernest Choy⁷, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Paris Descartes University, Paris, Ile-de-France, France, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Arthritis Associates, Palm Harbor, Tampa, FL, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
Abstract Number: 0828 • ACR Convergence 2020
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Stanley B Cohen¹, Yi-Hsing Chen², Naonobu Sugiyama³, Jose L Rivas⁴, Annette Diehl⁵, Tatjana Lukic⁶, Jerome Paulissen⁷, Haiyun Fan⁵, Tomohiro Hirose³ and Edward C Keystone⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Syneos Health, Morrisville, NC, ⁸Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: ORAL Shift (NCT02831855) was a 48-week Phase 3b/4 study, which demonstrated sustained efficacy/safety of tofacitinib modified release 11 mg once daily (QD) following MTX…
Abstract Number: 0972 • ACR Convergence 2020
Mapping Oligoclonally Expanded T Cells Within the Peripheral and Synovial Immune Landscape of Untreated ACPA+ Rheumatoid Arthritis Patients at the Single Cell Level
Pascale Wehr¹, Hendrik Nel¹, Chenhao Zhou², Ahmed Mehdi², Angelika Christ³, Helen Weedon⁴, Mihir Wechalekar⁵ and Ranjeny Thomas⁶, ¹University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³University of Queensland Institute for Molecular Bioscience, Brisbane, Australia, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵Flinders Medical Centre, Adelaide, South Australia, Australia, ⁶University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: Clonal T cell expansions – some large – have been identified in the peripheral blood (PB) and in synovial tissue (ST) of multiple joints…
Abstract Number: 1009 • ACR Convergence 2020
Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method
Ahmed Al-Saber¹, Adeeba Al-Herz², Jiazhu Pan¹, Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Aqeel Ghanem⁶, Mohammed Hussain⁵, Yaser Ali⁷, Ebrahim Nahar⁷, Ahmad Alenizi⁸, Sawsan Hayat⁷, Fatemah Abutiban⁹, Ali Aldei⁵, Amjad Alkadi¹⁰, Heba Alhajeri⁷, Husain Behbehani³, Naser Alhadhood³, Khaled Mokaddem⁵, Ahmed Khadrawy³, Ammad Fazal³, Agaz Zaman⁷, Ghada Mazloum⁷, Youssef Bartella⁵, Sally Hamed⁵ and Ramia Alsouk⁸, ¹Department of Mathematics and Statistics, University of Strathclyde, Glasgow, United Kingdom, ²Al-Amiri Hospital, Kuwait City, Kuwait, ³Farwania Hosiptal, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait University, Jabria, Kuwait, ⁵Al-Amiri Hospital, Kuwait, Kuwait, ⁶Mubarak Al-Kabeer Hospital, Kuwait City, Kuwait, ⁷Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁸Jahra Hospital, Jahra, Kuwait, ⁹Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ¹⁰Sabah Hospital, Kuwait, Kuwait
Background/Purpose: Missing data in clinical epidemiological researches violate the intention to treat principle, reduce statistical power and can induce bias if they are related to…
Abstract Number: 1180 • ACR Convergence 2020
External Validation of a Multi-biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients
Jeffrey R Curtis¹, Eric Sasso², Elena Hitraya², Cheryl Chin³, Richard Bamford³, Rotem Ben-Shachar³, Alexander Gutin³, Darl Flake³, Brent Mabey³ and Jerry Lanchbury³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Myriad Autoimmune, South San Francisco, CA, ³Myriad Genetics, Inc., Salt Lake City, UT
Background/Purpose: A novel score for predicting 3-year risk for CVD events in RA patients combines age, four traditional CVD risk factors (diabetes, hypertension, smoking, history…
Abstract Number: 1196 • ACR Convergence 2020
Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors
Austin Wheeler¹, Gail Kerr², Ilona Jileaeva³, Asha Krishna⁴, Bryant England¹, Harlan Sayles¹, Geoffrey Thiele¹, Jill Poole¹, Alison Petro¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Washington DC VA Medical Center, Washington, DC, ³Howard University Hospital, Washington, DC, ⁴Washington, D.C. VAMC, Washington, DC
Background/Purpose: Extra-articular manifestations of rheumatoid arthritis (RA), such as nodules and interstitial lung disease (ILD), portend poor outcomes and are more common in men than…
Abstract Number: 1212 • ACR Convergence 2020
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)
Peter Taylor¹, Bryan Downie², Emon Elboudwarej², Sam Kim², Angie Hertz², Amer Mirza², Jeff Siegel³, Rachael Hawtin² and Jinfeng Liu², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active RA. Previously, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].